Aurobindo Pharma Q4 net declines 12%, revenue rises over 11% to ₹6,472.96 crore

For the fiscal, the company reported a more than 27% decline in net profit to ₹1,927.6 crore

May 27, 2023 08:59 pm | Updated 09:46 pm IST - HYDERABAD

Drugmaker Aurobindo Pharma reported consolidated net profit for the March quarter declined more than 12% to ₹505.9 crore.

The lower net profit came even as revenue from operations increased more than 11% to ₹6,472.96 crore. Aiding the increase was a 51% increase in Formulations sales to ₹592 crore in ‘Growth Markets,’ including India, which also helped blunt the impact of a 32% decline in ARV revenue to ₹159 crore during the quarter.

During the quarter, U.S. formulations revenue increased 11.6% YoY to ₹3,045 crore, while Europe formulations revenue stood at ₹1,660 crore, an increase of 7.7%, the company said.   

“We saw decent performance in the quarter on the back of stable demand and pricing environment across our portfolio and geographies,” vice-chairman and MD K. Nityananda Reddy said in a release.

For the fiscal, the company reported a more than 27% decline in net profit to ₹1,927.6 crore even as revenue from operations increased 6% to ₹24,855.3 crore.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.